Scarica l'app Stockscreener
43.19
3.87%
1.61
Pre-mercato:
43.60
0.41
+0.95%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$41.58
Aprire:
$43.41
Volume 24 ore:
3.88M
Relative Volume:
1.81
Capitalizzazione di mercato:
$3.71B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-15.43
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
+0.58%
1M Prestazione:
+11.40%
6M Prestazione:
-3.23%
1 anno Prestazione:
-30.10%
Intervallo 1D:
$42.80
$45.60
Intervallo di 1 settimana:
$39.81
$45.60
Portata 52W:
$30.04
$63.68
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Confronta CRSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
43.19 | 3.71B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Citizens JMP reiterates CRISPR Therapeutics stock rating on in-vivo progress - Investing.com
SG Americas Securities LLC Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpShould You Buy? - MarketBeat
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
25,341 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Avanza Fonder AB - MarketBeat
Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million? - 24/7 Wall St.
Millennium Management LLC Trims Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Equities Analysts Set Expectations for CRSP FY2026 Earnings - MarketBeat
Crispr extends gains for the seventh consecutive trading day - MSN
Crispr Therapeutics: Betting On A One-Shot Future (NASDAQ:CRSP) - Seeking Alpha
Trend Tracker for (CRSP) - news.stocktradersdaily.com
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 6%Here's What Happened - MarketBeat
Crispr Therapeutics AG: Stock Soars Amid Bullish Trends - MSN
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? - Yahoo Finance
Crispr Therapeutics: Early-Stage Research Updates Show Promise (NASDAQ:CRSP) - Seeking Alpha
Cantor Fitzgerald Weighs in on CRSP FY2026 Earnings - Defense World
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts - Yahoo Finance
Crispr Therapeutics (CRSP) Rallies Amid FDA Fast-Tracking News - GuruFocus
Crispr extends gains for the seventh consecutive trading day (CRSP:NASDAQ) - Seeking Alpha
CRISPR Therapeutics AG shareholders approve key proposals By Investing.com - Investing.com South Africa
CRISPR Therapeutics AG Shareholders Approve Key Proposals - TipRanks
CRISPR Therapeutics AG shareholders approve key proposals - Investing.com
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It - Benzinga
Wealth Enhancement Advisory Services LLC Has $1.08 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - MSN
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month - simplywall.st
Crispr: Shares Very Undervalued, as Early-Stage Pipeline Makes Progress and Casgevy Launch Underway - Morningstar
CRSP Sees Significant Increase in Bullish Option Activity | CRSP Stock News - GuruFocus
Crispr Therapeutics call volume above normal and directionally bullish - TipRanks
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Raised by Green Alpha Advisors LLC - MarketBeat
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - sharewise
Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG - TipRanks
Can CRISPR Build On Casgevy's Success With Its In Vivo Pipeline? - Barchart.com
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Voloridge Investment Management LLC - MarketBeat
Capital Market Strategies LLC Buys 9,652 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Q2 EPS Forecast for CRISPR Therapeutics Increased by Analyst - MarketBeat
Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) Insider Sells 3,932 Shares of Stock - MarketBeat
Cas9 Technology Market Projected to Hit $30.4 Billion at a 19.81% CAGR by 2032 - industrytoday.co.uk
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Deutsche Bank AG - Defense World
Trading (CRSP) With Integrated Risk Controls - news.stocktradersdaily.com
Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):